405230-90-2

Basic information

• Product Name: 2-Chloro-5-fluoro-3-nitro-4-pyridinaMine
• Synonyms: 2-Chloro-5-fluoro-3-nitro-4-pyridinaMine;4-PyridinaMine, 2-chloro-5-fluoro-3-nitro-;2-Chloro-5-fluoro-3-nitro-pyridin-4-ylaMine;4-AMINO-2-CHLORO-5-FLUORO-3-NITROPYRIDINE
• CAS NO: 405230-90-2
• Molecular Formula: C₅H₃ClFN₃O₂
• Molecular Weight: 191.5476232
• Mol File: 405230-90-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-Chloro-5-fluoro-3-nitro-4-pyridinaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-fluoro-3-nitro-4-pyridinaMine(405230-90-2)
• EPA Substance Registry System: 2-Chloro-5-fluoro-3-nitro-4-pyridinaMine(405230-90-2)

Safety Data

• Hazardous Substances Data: 405230-90-2(Hazardous Substances Data)

Usage

General Description

2-Chloro-5-fluoro-3-nitro-4-pyridinamine is a chemical compound with the formula C5H3ClFN3O2. It is a fluorinated pyridine derivative with a nitro group and a chloro group attached to the pyridine ring. 2-Chloro-5-fluoro-3-nitro-4-pyridinaMine is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis. 2-Chloro-5-fluoro-3-nitro-4-pyridinamine has potential applications in the field of medicinal chemistry due to its interesting chemical and biological properties.

Upstream product

• 405230-80-0 2-chloro-5-fluoro-4-nitropyridine-1-oxide 
• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 
• 405230-79-7 2-chloro-5-fluoropyridine-1-oxide 
• 405230-86-6 2-chloro-5-fluoro-4-nitraminopyridine 
• 31301-51-6 2-chloro-5-fluoropyridine 

Downstream Products

• 405230-93-5 2-chloro-3,4-diamino-5-fluoropyridine 
• 1334411-83-4 4-bromo-2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 1334411-84-5 4-chloro-7-fluoro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 1334407-23-6 N-(2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-yl)cyclopropanecarboxamide 
• 1334407-22-5 2-(2,6-dichlorophenyl)-N-(2,6-dimethylpyrimidin-4-yl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-amine 
• 405231-08-5 4-chloro-7-fluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 405230-97-9 4-chloro-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 202806-40-4 3-deaza-3-fluoro-adenosine 

Relevant articles and documents

Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy

Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.

Novel nucleosides and related processes, pharmaceutical compositions and methods

The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-β-D-ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.